Ying Yuan

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint Dose-response curve estimation: a semiparametric mixture approach
    Ying Yuan
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 67:1543-54. 2011
  2. pmc Bayesian hybrid dose-finding design in phase I oncology clinical trials
    Ying Yuan
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Stat Med 30:2098-108. 2011
  3. pmc Bayesian mediation analysis
    Ying Yuan
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Psychol Methods 14:301-22. 2009
  4. ncbi request reprint Bayesian quantile regression for longitudinal studies with nonignorable missing data
    Ying Yuan
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 66:105-14. 2010
  5. ncbi request reprint Mixed-effect hybrid models for longitudinal data with nonignorable dropout
    Ying Yuan
    Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 65:478-86. 2009
  6. ncbi request reprint Sequential continual reassessment method for two-dimensional dose finding
    Ying Yuan
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, U S A
    Stat Med 27:5664-78. 2008
  7. ncbi request reprint Meta-analysis of studies with missing data
    Ying Yuan
    Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 65:487-96. 2009
  8. pmc A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial
    Ying Yuan
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Stat Med 30:1218-29. 2011
  9. doi request reprint A latent contingency table approach to dose finding for combinations of two agents
    Guosheng Yin
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 65:866-75. 2009
  10. pmc A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells
    Norihiko Saito
    Department of Neuro Oncology, Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Stem Cells 32:301-12. 2014

Detail Information

Publications25

  1. doi request reprint Dose-response curve estimation: a semiparametric mixture approach
    Ying Yuan
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 67:1543-54. 2011
    ..We conduct extensive simulation studies to investigate the performance of the proposed methods and illustrate them with two real examples...
  2. pmc Bayesian hybrid dose-finding design in phase I oncology clinical trials
    Ying Yuan
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Stat Med 30:2098-108. 2011
    ..The simulation results show that our design is more robust than parametric model-based methods and more efficient than nonparametric model-free methods...
  3. pmc Bayesian mediation analysis
    Ying Yuan
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Psychol Methods 14:301-22. 2009
    ..Simulation studies and analysis of 2 data sets are used to illustrate the proposed methods. (PsycINFO Database Record (c) 2009 APA, all rights reserved)...
  4. ncbi request reprint Bayesian quantile regression for longitudinal studies with nonignorable missing data
    Ying Yuan
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 66:105-14. 2010
    ..We assess the performance of the proposed method using simulation studies, and illustrate it with data from a pediatric AIDS clinical trial...
  5. ncbi request reprint Mixed-effect hybrid models for longitudinal data with nonignorable dropout
    Ying Yuan
    Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 65:478-86. 2009
    ..Because SPMs are nested within MEHMs, likelihood ratio tests can be constructed to evaluate the conditional independence assumption of SPMs. We use data from a pediatric AIDS clinical trial to illustrate the models...
  6. ncbi request reprint Sequential continual reassessment method for two-dimensional dose finding
    Ying Yuan
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, U S A
    Stat Med 27:5664-78. 2008
    ..We illustrate the design through extensive simulation studies motivated by clinical trials evaluating multiple drugs or dose and schedule combinations...
  7. ncbi request reprint Meta-analysis of studies with missing data
    Ying Yuan
    Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 65:487-96. 2009
    ..We illustrate these methods through a meta-analysis of 16 published randomized trials that examined combined pharmacotherapy and psychological treatment for depression...
  8. pmc A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial
    Ying Yuan
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Stat Med 30:1218-29. 2011
    ..We illustrate the proposed design through its application to a phase II leukemia clinical trial, and evaluate its operating characteristics through simulation studies...
  9. doi request reprint A latent contingency table approach to dose finding for combinations of two agents
    Guosheng Yin
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 65:866-75. 2009
    ..Finally, we illustrate our dose-finding procedure with a clinical trial of agent combinations at M. D. Anderson Cancer Center...
  10. pmc A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells
    Norihiko Saito
    Department of Neuro Oncology, Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Stem Cells 32:301-12. 2014
    ..Our results suggest that proneural GBM characterized by high Notch pathway activation may exhibit greater sensitivity to γ secretase inhibitor treatment, holding a promise to improve the efficiency of current glioma therapy...
  11. ncbi request reprint Parametric and semiparametric model-based estimates of the finite population mean for two-stage cluster samples with item nonresponse
    Ying Yuan
    Department of Biostatistics and Applied Mathematics, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 63:1172-80. 2007
    ..These new methods are compared with existing approaches by simulation. The National Health and Nutrition Examination Survey data are used to illustrate these approaches...
  12. pmc Bayesian adaptive phase II screening design for combination trials
    Chunyan Cai
    Biostatistics Epidemiology Research Design Core, Center for Clinical and Translational Sciences, The University of Texas Health Science Center at Houston, Houston, TX, USA
    Clin Trials 10:353-62. 2013
    ....
  13. pmc DeMix: deconvolution for mixed cancer transcriptomes using raw measured data
    Jaeil Ahn
    Department of Bioinformatics and Computational Biology and Department of Biostatistics, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Bioinformatics 29:1865-71. 2013
    ....
  14. pmc Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma
    Shlomit Yust-Katz
    Department of Neuro Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 119:2747-53. 2013
    ..Lonafarnib is an oral selective farnesyltransferase inhibitor, a class of drugs which have shown activity in preclinical glioma models. Temozolomide (TMZ) is an alkylating agent that is the first-line chemotherapy for glioblastoma...
  15. doi request reprint Feasibility of an expressive-disclosure group intervention for post-treatment colorectal cancer patients: results of the Healthy Expressions study
    Cindy L Carmack
    Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer 117:4993-5002. 2011
    ..Thus, the authors developed and tested the efficacy of a 12-session combined written and verbal expression group program for psychologically distressed colorectal cancer (CRC) patients...
  16. doi request reprint Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer
    Huong T Le-Petross
    Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:3900-7. 2011
    ..In this study, the authors investigated the efficacy of alternating screening mammography and breast MRI every 6 months in women who had a genetically high risk of developing breast cancer...
  17. pmc Bayesian latent-class mixed-effect hybrid models for dyadic longitudinal data with non-ignorable dropouts
    Jaeil Ahn
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, U S A Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, U S A
    Biometrics 69:914-24. 2013
    ..We evaluate the performance of the proposed method using a simulation study, and apply our method to a longitudinal dyadic data set that arose from a prostate cancer trial. ..
  18. pmc Goodness-of-fit diagnostics for Bayesian hierarchical models
    Ying Yuan
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 68:156-64. 2012
    ..The proposed methodology is illustrated in a clinical application; an application to discrete data is described in supplementary material...
  19. doi request reprint Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity
    Xiudong Lei
    Department of Biostatistics, Unit 1411, The University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Lifetime Data Anal 17:156-74. 2011
    ..D. Anderson Cancer Center, we conduct extensive simulation studies under various scenarios to investigate the performance of the proposed method, and compare it with available Bayesian adaptive randomization procedures...
  20. pmc Evaluation of image registration spatial accuracy using a Bayesian hierarchical model
    Suyu Liu
    Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas, U S A
    Biometrics 70:366-77. 2014
    ..We develop a Gibbs sampling algorithm to efficiently fit our models to high-dimensional data, and apply the proposed method to analyze an image dataset obtained from a 4D thoracic CT study...
  21. pmc Clinical and prognostic features of adult patients with gangliogliomas
    Shlomit Yust-Katz
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas S Y K, D L, J F de G Department of Neurology, The University of Mississippi Medical Center, Jackson, Mississippi M D A Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas J W, Y Y Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas A O, G N F Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas P D B
    Neuro Oncol 16:409-13. 2014
    ..Gangliogliomas (GGs) represent <1% of primary brain tumors in adults. Little is known regarding prognostic features, clinical characteristics, or the impact of treatment on patient outcomes...
  22. pmc Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells
    Jun Fu
    Brain Tumor Center, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 73:3062-74. 2013
    ..Our results suggest that GBM characterized by high-expressing Olig2 GIC may exhibit greater sensitivity to NVP-HSP990 treatment, establishing a foundation for further investigation of the role of HSP90 signaling in GBM...
  23. pmc Identification of common prognostic gene expression signatures with biological meanings from microarray gene expression datasets
    Jun Yao
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    PLoS ONE 7:e45894. 2012
    ..These results demonstrate the power of SCoR to identify common and biologically meaningful prognostic gene expression signatures...
  24. pmc Robust mediation analysis based on median regression
    Ying Yuan
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center
    Psychol Methods 19:1-20. 2014
    ..We illustrate the proposed method using data from a program designed to increase reemployment and enhance mental health of job seekers. (PsycINFO Database Record (c) 2014 APA, all rights reserved). ..
  25. pmc Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
    Anas Younes
    Departments of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 119:4123-8. 2012
    ..Our results demonstrate that the addition of rituximab to ABVD is safe and has a promising clinical activity in patients with advanced-stage cHL. These data are currently being confirmed in a multicenter randomized trial...